Charles Schwab Investment Management Inc. Increases Position in Pacira BioSciences, Inc. (NASDAQ:PCRX)

Charles Schwab Investment Management Inc. increased its stake in Pacira BioSciences, Inc. (NASDAQ:PCRX) by 16.3% in the fourth quarter, HoldingsChannel.com reports. The firm owned 502,204 shares of the company’s stock after acquiring an additional 70,307 shares during the quarter. Charles Schwab Investment Management Inc.’s holdings in Pacira BioSciences were worth $9,462,000 at the end of the most recent reporting period.

A number of other large investors have also made changes to their positions in the stock. China Universal Asset Management Co. Ltd. increased its holdings in Pacira BioSciences by 10.3% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 9,790 shares of the company’s stock valued at $184,000 after acquiring an additional 918 shares in the last quarter. Caitlin John LLC increased its holdings in Pacira BioSciences by 1,850.0% during the 4th quarter. Caitlin John LLC now owns 1,872 shares of the company’s stock valued at $35,000 after acquiring an additional 1,776 shares in the last quarter. Nisa Investment Advisors LLC increased its holdings in Pacira BioSciences by 495.3% during the 4th quarter. Nisa Investment Advisors LLC now owns 3,304 shares of the company’s stock valued at $62,000 after acquiring an additional 2,749 shares in the last quarter. Quest Partners LLC increased its holdings in Pacira BioSciences by 137.6% during the 3rd quarter. Quest Partners LLC now owns 9,410 shares of the company’s stock valued at $142,000 after acquiring an additional 5,449 shares in the last quarter. Finally, Virtus Investment Advisers Inc. purchased a new position in Pacira BioSciences during the 3rd quarter valued at about $98,000. Hedge funds and other institutional investors own 99.73% of the company’s stock.

Pacira BioSciences Price Performance

Pacira BioSciences stock opened at $24.14 on Friday. The firm’s 50-day moving average is $24.44 and its two-hundred day moving average is $19.58. The company has a debt-to-equity ratio of 0.51, a current ratio of 2.25 and a quick ratio of 1.89. Pacira BioSciences, Inc. has a 12-month low of $11.16 and a 12-month high of $31.67. The stock has a market capitalization of $1.12 billion, a P/E ratio of -11.89 and a beta of 0.86.

Analyst Ratings Changes

Several research firms have weighed in on PCRX. HC Wainwright raised their target price on shares of Pacira BioSciences from $57.00 to $70.00 and gave the company a “buy” rating in a report on Friday, February 28th. Royal Bank of Canada restated a “sector perform” rating and set a $18.00 target price on shares of Pacira BioSciences in a report on Tuesday, January 14th. Needham & Company LLC raised their target price on shares of Pacira BioSciences from $30.00 to $32.00 and gave the company a “buy” rating in a report on Friday, February 28th. Truist Financial raised shares of Pacira BioSciences from a “sell” rating to a “hold” rating and raised their price target for the stock from $8.00 to $25.00 in a research note on Thursday, January 30th. Finally, Barclays raised their price target on shares of Pacira BioSciences from $17.00 to $24.00 and gave the stock an “overweight” rating in a research note on Friday, February 28th. One investment analyst has rated the stock with a sell rating, four have given a hold rating and five have given a buy rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and an average target price of $27.22.

Pacira BioSciences Company Profile

Pacira Biosciences, Inc is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients’ journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.